Myoblast Transplantation: What's Going on?
Muscle tissue, due to its syncytial cellular structure and specific nerve and vascular requirements, cannot be transplanted as an organ. In an effort to use transplantation to overcome genetically determined biochemical deficiencies in muscle, attention has focused on delivering the developmental pr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
1993-01-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/096368979300200107 |
| id |
doaj-77f0ea226ede42a48185c30005110af2 |
|---|---|
| record_format |
Article |
| spelling |
doaj-77f0ea226ede42a48185c30005110af22020-11-25T03:16:57ZengSAGE PublishingCell Transplantation0963-68971555-38921993-01-01210.1177/096368979300200107Myoblast Transplantation: What's Going on?Eric P. Hoffman0Department of Molecular Genetics and Biochemistry, Department of Human Genetics, and Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USAMuscle tissue, due to its syncytial cellular structure and specific nerve and vascular requirements, cannot be transplanted as an organ. In an effort to use transplantation to overcome genetically determined biochemical deficiencies in muscle, attention has focused on delivering the developmental precursors of mature muscle fibers, myoblasts, as donor cells for cellular transplantation. Consequent to a brief report showing limited success of the technique in mice in 1988, human trials were summarily designed, funded, and initiated. The human trials have spurred more controversy than concrete data, with more reports appearing in the popular press than in scientific journals. This review summarizes the events leading to the current state of affairs, and underscores the biological hurdles facing myoblast transplantation before it can be considered a therapeutic modality.https://doi.org/10.1177/096368979300200107 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Eric P. Hoffman |
| spellingShingle |
Eric P. Hoffman Myoblast Transplantation: What's Going on? Cell Transplantation |
| author_facet |
Eric P. Hoffman |
| author_sort |
Eric P. Hoffman |
| title |
Myoblast Transplantation: What's Going on? |
| title_short |
Myoblast Transplantation: What's Going on? |
| title_full |
Myoblast Transplantation: What's Going on? |
| title_fullStr |
Myoblast Transplantation: What's Going on? |
| title_full_unstemmed |
Myoblast Transplantation: What's Going on? |
| title_sort |
myoblast transplantation: what's going on? |
| publisher |
SAGE Publishing |
| series |
Cell Transplantation |
| issn |
0963-6897 1555-3892 |
| publishDate |
1993-01-01 |
| description |
Muscle tissue, due to its syncytial cellular structure and specific nerve and vascular requirements, cannot be transplanted as an organ. In an effort to use transplantation to overcome genetically determined biochemical deficiencies in muscle, attention has focused on delivering the developmental precursors of mature muscle fibers, myoblasts, as donor cells for cellular transplantation. Consequent to a brief report showing limited success of the technique in mice in 1988, human trials were summarily designed, funded, and initiated. The human trials have spurred more controversy than concrete data, with more reports appearing in the popular press than in scientific journals. This review summarizes the events leading to the current state of affairs, and underscores the biological hurdles facing myoblast transplantation before it can be considered a therapeutic modality. |
| url |
https://doi.org/10.1177/096368979300200107 |
| work_keys_str_mv |
AT ericphoffman myoblasttransplantationwhatsgoingon |
| _version_ |
1724633999905652736 |